Cybin announces approval of first-in-human dosing of its proprietary dmt molecule cyb004

Toronto--( business wire )--cybin inc. (neo:cybn) (nyse american:cybn) (“cybin” or the “company”), a biopharmaceutical company focused on progressing psychedelics to therapeutics® is pleased to announce that it has received approval from an independent ethics committee in the netherlands to initiate first-in-human dosing of its proprietary deuterated n,n-dimethyltryptamine (“dmt”) molecule cyb004 through a protocol amendment to its ongoing cyb004-e phase 1 trial. this clinical advancement marks the first time a deuterated dmt molecule will be evaluated in humans and further reduces cybin's time-to-clinic with cyb004.
CYBN Ratings Summary
CYBN Quant Ranking